• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Opthea Limited (Amendment)

    2/14/24 4:21:51 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $OPT alert in real time by email
    SC 13G/A 1 tm242424d23_sc13ga.htm SC 13G/A

     

     

    SCHEDULE 13G

     

    SECURITIES AND EXCHANGE COMMISSION

     

    WASHINGTON, DC 20549

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*

     

    Opthea Limited

    (Name of Issuer)

     

    Ordinary Shares, no par value

    (Title of Class of Securities)

     

    68386J208**

     

    (CUSIP Number)

     

    December 31, 2023

     
     

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    xRule 13d-1(b)

     

    ¨Rule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of Securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that Section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

     

    **This CUSIP applies to the American Depositary Shares, each representing eight Ordinary Shares

     

     

     

     

     

    CUSIP No. 68386J208

     

     

    1

     

     

    NAMES OF REPORTING PERSONS

    Baker Bros. Advisors LP

     

     

    2

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

     

    (a) ¨

    (b) ¨

     

     

    3

     

     

    SEC USE ONLY

     

     

    4

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

     

    5

     

     

    SOLE VOTING POWER

    28,100,345 (1)

     

     

    6

     

     

    SHARED VOTING POWER

    -0-

     

     

    7

     

     

    SOLE DISPOSITIVE POWER

    28,100,345 (1)

     

     

    8

     

     

    SHARED DISPOSITIVE POWER

    -0-

     

     

    9

     

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    28,100,345 (1)

     

     

    10

     

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (See Instructions)

     

     

    ¨

     

    11

     

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.2% (1)(2)

     

     

    12

     

     

    TYPE OF REPORTING PERSON (See Instructions)

    IA, PN

     

     

      (1) Includes 20,709,160 Ordinary Shares (“Ordinary Shares”) of Opthea Limited (the “Issuer”) that are represented by 2,588,645 American Depositary Shares (“ADS”) directly held by Baker Brothers Life Sciences, L.P. (“Life Sciences”) and 667, L.P. (“667”, and together with Life Sciences, the “Funds”). Each ADS represents 8 Ordinary Shares of the Issuer.
      (2) Based on 662,808,634 Ordinary Shares of the Issuer outstanding as of December 21, 2023, as reported in the Issuer’s Notification of Issue, Conversion or Payment up of Unquoted Equity Securities filed with the Australian Stock Exchange (the “ASX”) on December 21, 2023.

      

     

     

     

    CUSIP No. 68386J208

     

     

    1

     

     

    NAMES OF REPORTING PERSONS

    Baker Bros. Advisors (GP) LLC

     

     

    2

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

     

    (a) ¨

    (b) ¨

     

     

    3

     

     

    SEC USE ONLY

     

     

    4

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

     

    5

     

     

    SOLE VOTING POWER

    28,100,345 (1)

     

     

    6

     

     

    SHARED VOTING POWER

    -0-

     

     

    7

     

     

    SOLE DISPOSITIVE POWER

    28,100,345 (1)

     

     

    8

     

     

    SHARED DISPOSITIVE POWER

    -0-

     

     

    9

     

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    28,100,345 (1)

     

     

    10

     

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (See Instructions)

     

     

    ¨

     

    11

     

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.2% (1)
    (2)

     

     

    12

     

     

    TYPE OF REPORTING PERSON (See Instructions)

    HC, OO

     

     

      (1) Includes 20,709,160 Ordinary Shares of the Issuer that are represented by 2,588,645 ADS directly held by the Funds. Each ADS represents 8 Ordinary Shares of the Issuer.
      (2) Based on 662,808,634 Ordinary Shares of the Issuer outstanding as of December 21, 2023, as reported in the Issuer’s Notification of Issue, Conversion or Payment up of Unquoted Equity Securities filed with the ASX on December 21, 2023.

     

     

     

     

    CUSIP No. 68386J208

     

     

    1

     

     

    NAMES OF REPORTING PERSONS

    Felix J. Baker

     

     

    2

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

     

    (a) ¨

    (b) ¨

     

     

    3

     

     

    SEC USE ONLY

     

     

    4

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

     

    5

     

     

    SOLE VOTING POWER

    28,100,345 (1)

     

     

    6

     

     

    SHARED VOTING POWER

    -0-

     

     

    7

     

     

    SOLE DISPOSITIVE POWER

    28,100,345 (1)

     

     

    8

     

     

    SHARED DISPOSITIVE POWER

    -0-

     

     

    9

     

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    28,100,345 (1)

     

     

    10

     

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (See Instructions)

     

     

    ¨

     

    11

     

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.2% (1)
    (2)

     

     

    12

     

     

    TYPE OF REPORTING PERSON (See Instructions)

    IN, HC

     

     

      (1) Includes 20,709,160 Ordinary Shares of the Issuer that are represented by 2,588,645 ADS directly held by the Funds. Each ADS represents 8 Ordinary Shares of the Issuer.
      (2) Based on 662,808,634 Ordinary Shares of the Issuer outstanding as of December 21, 2023, as reported in the Issuer’s Notification of Issue, Conversion or Payment up of Unquoted Equity Securities filed with the ASX on December 21, 2023.

     

     

     

     

    CUSIP No. 68386J208

     

     

    1

     

     

    NAMES OF REPORTING PERSONS

    Julian C. Baker

     

     

    2

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

     

    (a) ¨

    (b) ¨

     

     

    3

     

     

    SEC USE ONLY

     

     

    4

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

     

    5

     

     

    SOLE VOTING POWER

    28,100,345 (1)

     

     

    6

     

     

    SHARED VOTING POWER

    -0-

     

     

    7

     

     

    SOLE DISPOSITIVE POWER

    28,100,345 (1)

     

     

    8

     

     

    SHARED DISPOSITIVE POWER

    -0-

     

     

    9

     

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    28,100,345 (1)

     

     

    10

     

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (See Instructions)

     

     

    ¨

     

    11

     

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.2% (1)
    (2)

     

     

    12

     

     

    TYPE OF REPORTING PERSON (See Instructions)

    IN, HC

     

     

     

      (1) Includes 20,709,160 Ordinary Shares of the Issuer that are represented by 2,588,645 ADS directly held by the Funds. Each ADS represents 8 Ordinary Shares of the Issuer.
      (2) Based on 662,808,634 Ordinary Shares of the Issuer outstanding as of December 21, 2023, as reported in the Issuer’s Notification of Issue, Conversion or Payment up of Unquoted Equity Securities filed with the ASX on December 21, 2023.

      

     

     

     

    Amendment No. 3 to Schedule 13G

     

    This Amendment No. 3 to Schedule 13G amends and restates the previously filed Schedule 13G filed by Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP) LLC (the “Adviser GP”), Julian C. Baker and Felix J. Baker (collectively, the “Reporting Persons”). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect.

     

    Item 1(a)Name of Issuer:

     

    Opthea Limited (the “Issuer”)

     

    Item 1(b)Address of Issuer’s Principal Executive Offices:

     

    650 Chapel Street, Level 4

     

    South Yarra, Victoria, Australia 3141

     

    Item 2(a)Name of Person Filing:

     

    This Amendment No. 3 is being filed jointly by the Reporting Persons.

     

    Item 2(b)Address of Principal Business Office or, if None, Residence:

     

    The business address of each of the Reporting Persons is:

     

    c/o Baker Bros. Advisors LP

     

    860 Washington Street, 3rd Floor

     

    New York, NY 10014

     

    (212) 339-5690

     

    Item 2(c)Citizenship:

     

    The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.

     

    Item 2(d)Title of Class of Securities:

     

    Ordinary Shares, no par value per share (“Ordinary Shares”).

     

    Item 2(e)CUSIP Number:

     

    68386J208

     

     

     

     

    Item 3If this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a:

     

      (a)  ¨ Broker or dealer registered under Section 15 of the Exchange Act.
       
      (b)  ¨ Bank as defined in Section 3(a)(6) of the Exchange Act.
       
      (c)  ¨ Insurance company as defined in Section 3(a)(19) of the Exchange Act.
       
      (d)  ¨ Investment company registered under Section 8 of the Investment Company Act of 1940.
       
      (e)  x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
       
      (f)  ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
       
      (g)  x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
       
      (h)  ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
       
      (i)  ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940.
       
      (j)  ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

     

    Item 4Ownership:

     

    Items 5 through 9 and 11 of each of the cover pages to this Amendment No. 3 are incorporated herein by reference. Set forth below is the aggregate number of Ordinary Shares, 20,709,160 of which are represented by 2,588,645 American Depositary Shares (“ADS”), directly held by Baker Brothers Life Sciences, L.P. (“Life Sciences”) and 667, L.P. (“667”, and together with Life Sciences, the “Funds”), all of which may be deemed to be indirectly beneficially owned by the Reporting Persons. Each ADS represents 8 Ordinary Shares of the Issuer.

     

    The information set forth below is based on 662,808,634 Ordinary Shares outstanding as of December 21, 2023 as reported in the Issuer’s Notification of Issue, Conversion or Payment up of Unquoted Equity Securities filed with the Australian Stock Exchange (“ASX”) on December 21, 2023. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended.

     

     

     

     

    Name   Number of Ordinary Shares
    we own or have the right to
    acquire within 60 days
      Percent of
    Class
    Outstanding
     
    667, L.P.   2,253,850   0.3 %
    Baker Brothers Life Sciences, L.P.   25,846,495   3.9 %
    Total   28,100,345   4.2 %

     

    Pursuant to the management agreements, as amended, among the Adviser, the Funds and their respective general partners, the Funds’ respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds and thus the Adviser has complete and unlimited discretion and authority with respect to the Funds’ investments and voting power over investments.

     

    The Adviser GP is the sole general partner of the Adviser. The Adviser GP, Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, and the Adviser may be deemed to be beneficial owners of Securities of the Issuer directly held by the Funds.

     

    Item 5Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of Securities, check the following x.

     

    Item 6Ownership of More than Five Percent on Behalf of Another Person:

     

    N/A

     

    Item 7Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    The information in Item 4 is incorporated herein by reference.

     

    Item 8Identification and Classification of Members of the Group:

     

    N/A

     

    Item 9 Notice of Dissolution of Group:

     

    N/A

     

    Item 10Certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the Securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the Securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 14, 2024

     

     

    BAKER BROS. ADVISORS LP

     

    By: Baker Bros. Advisors (GP) LLC, its general partner

         
      By: /s/ Scott L. Lessing
        Name: Scott L. Lessing
    Title: President

     

      BAKER BROS. ADVISORS (GP) LLC
         
      By: /s/ Scott L. Lessing
        Name: Scott L. Lessing
    Title: President

     

      /s/ Julian C. Baker
      Julian C. Baker
     
      /s/ Felix J. Baker
      Felix J. Baker

     

     

     

    Get the next $OPT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OPT

    DatePrice TargetRatingAnalyst
    3/25/2025$2.00Buy → Neutral
    H.C. Wainwright
    3/25/2025$12.00 → $1.00Outperform → Market Perform
    Leerink Partners
    3/25/2025$8.00 → $1.00Buy → Underperform
    Jefferies
    3/24/2025Outperform → Perform
    Oppenheimer
    12/8/2022$14.00Buy
    H.C. Wainwright
    4/26/2022$25.00Outperform
    SVB Leerink
    More analyst ratings

    $OPT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Opthea Announces Decision to Discontinue Wet AMD Trials

      ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe trials Opthea continues to consider impact of negative trial results under its Development Funding Agreement (DFA) and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced updates on i

      3/31/25 12:01:00 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Opthea Announces COAST Phase 3 Trial Topline Results

      COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced results from its global Phase 3 clinical trial COAST (Combination OPT-302 with Aflibercept Study) in patients with wet AMD

      3/24/25 12:01:00 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Opthea Announces Phase 2b Wet AMD Publication

      Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina MELBOURNE, Australia and PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the publication of sozinibercept Phase 2b data in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging (OSLI) Retina. The paper entitled "Sozinibercept Combination Therapy for Neovascula

      3/3/25 7:00:00 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Opthea Limited

      SC 13G/A - Opthea Ltd (0001815620) (Subject)

      11/14/24 6:00:28 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Opthea Limited

      SC 13G/A - Opthea Ltd (0001815620) (Subject)

      7/3/24 7:15:39 PM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Opthea Limited (Amendment)

      SC 13G/A - Opthea Ltd (0001815620) (Subject)

      2/14/24 4:21:51 PM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OPT
    SEC Filings

    See more
    • SEC Form 6-K filed by Opthea Limited

      6-K - Opthea Ltd (0001815620) (Filer)

      4/10/25 6:05:23 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Opthea Limited

      6-K - Opthea Ltd (0001815620) (Filer)

      3/31/25 6:07:14 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Opthea Limited

      6-K - Opthea Ltd (0001815620) (Filer)

      3/24/25 6:06:42 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OPT
    Financials

    Live finance-specific insights

    See more
    • Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD

      MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Opthea Limited ((ASX:OPT, NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce that MST Access will host an "Ask the Expert" conference call with Professor Jason S. Slakter, M.D. on Tuesday 13th December 6:30pm – 7:30pm EST USA (Wednesday 14th December 10:30am – 11:30am AEDT). Prof Slakter is a board certified Retinal and Macular Disease Specialist, Clinical Professor of Ophthalmology at New York University School of Medicine, and partner of Vitreous Retina Macula Consultants of New York. Prof Slakter will present an overview of Opthea'

      12/12/22 10:08:46 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OPT
    Leadership Updates

    Live Leadership Updates

    See more
    • Opthea Appoints Kathy Connell to Board of Directors

      Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of Kathy Connell, GAICD, to the Board of Directors (the "Board") as a Non-Executive Director. Ms. Connell's appointment was effective immediately after the Annual General Meeting of the

      11/15/24 7:00:48 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025

      Parisa Zamiri, MD, PhD, and Tom Reilly respectively appointed CMO and CFO Anand Sundaram appointed Vice President Marketing MELBOURNE, Australia and PRINCETON, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced three senior hires as the Company continues to prepare for the sozinibercept Phase 3 topline data readouts of COAST anticipated in early Q2 calendar year 2025 and ShORe in mid calendar year 2025. "Opthea is at an inflection point with

      10/8/24 7:00:00 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board

      MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announces the formation of its Medical Advisory Board ("MAB") composed of 10 retina thought leaders from countries around the world including the US, Argentina, Australia, China, France, Germany, and Israel. Chaired by Arshad M. Khanani, MD, MA, FASRS, Chief Medical Advisor of Opthea, the MAB's role is to advise the Company on opportunities to address the unmet medical

      7/17/24 7:15:00 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Opthea Ltd. downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Opthea Ltd. from Buy to Neutral and set a new price target of $2.00

      3/25/25 8:30:12 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Opthea Ltd. downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Opthea Ltd. from Outperform to Market Perform and set a new price target of $1.00 from $12.00 previously

      3/25/25 8:25:42 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Opthea Ltd. downgraded by Jefferies with a new price target

      Jefferies downgraded Opthea Ltd. from Buy to Underperform and set a new price target of $1.00 from $8.00 previously

      3/25/25 8:25:11 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care